Chimerigen

Chimerigen, now a subsidiary of Adipogen Life Sciences, is a biotechnology company specializing in the development and manufacture of high-quality recombinant fusion proteins for the life sciences research market. The company is renowned for its proprietary non-lytic Ig-fusion protein technology, which utilizes a modified Fc region to eliminate effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This modification provides researchers with highly specific tools for studying receptor-ligand interactions in both in vivo and in vitro settings without the interference of lytic activity. Their extensive product portfolio focuses heavily on the TNF receptor superfamily and immune checkpoint proteins, serving as critical reagents for the development of next-generation immunotherapies. Since its acquisition in 2014, Chimerigen has continued to operate as a specialized brand, providing essential tools for immunology and oncology research globally.